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po the Editor: Intracoronary injection of bone marrow cells (BMC)
as been introduced for improvement of left ventricular (LV)
unction after acute myocardial infarction (AMI). In the random-
zed ASTAMI (Autologous Stem cell Transplantation in Acute
yocardial Infarction) study, BMC treatment did not improve LV
unction after 6 months (1). The aim of this ASTAMI substudy was
o investigate effects of BMC therapy on safety, clinical outcome, and
erial changes in LV function during a 12-month follow-up.
The study design has been described previously (1). We ran-
omized 100 patients between 40 and 75 years of age with anterior
MI to either intracoronary injection of autologous mononuclear
one marrow cells (mBMC) 4 to 8 days after the acute event (n 
0) or to a control group (n  50). All received percutaneous
oronary intervention (PCI) with stenting of left anterior descend-
ng (LAD) culprit lesions 2 to 12 h after onset of symptoms.
icoll-hypaque density gradient centrifugation was used to isolate
BMC from 50 ml bone marrow. Median cell viability was 95%
interquartile range 94% to 97%), the number of injected viable
BMC 68 x 106 (interquartile range 54  106 to 130  106), and
D34 cells 0.7  106 (interquartile range 0.4  106 to 1.6 
06). A PCI stop-flow technique was used for injecting mBMC in
he LAD (1). Three mBMC group patients did not receive cell
reatment (1). Echocardiograms were obtained in all patients at
aseline (4.5  1.1 days after PCI) and at 3, 6, and 12 months,
igitally stored, blinded, and analyzed as previously described (1)
ccording to guidelines (2).
Signal-averaged electrocardiogram (ECG) (GE MAC 5000,
E Healthcare, Waukesha, Wisconsin) and 24-h Holter moni-
oring (Medilog FD4 and Medilog Excel-3 12.0 software, Oxford
nstruments, Abingdon, United Kingdom) were obtained at base-
ine. Signal-averaged ECG was repeated at 3 months and Holter
onitoring at 6 months.
Angiograms were obtained at 12.5 images/s in all patients after
cute PCI and at 6-month follow-up and stored digitally. Quan-
itative coronary angiography was analyzed with CMS Medis
oftware (Sectra Imtec AB, Linkøping, Sweden) by a single
nvestigator (A.R.) unaware of treatment allocation.
Variables are presented as mean  SD, median (interquartile
ange), or number (proportion), and groups were compared with
he 2-sample t test, Mann-Whitney test, chi-square test, or
isher’s exact test as appropriate. We used general linear regression
o analyze the mean response over time (3). Variables with single
ollow-up measurements were compared with analysis of covari- (nce. We used SPSS version 14.0 (SPSS Inc., Chicago, Illinois).
ntention-to-treat was used throughout. Values of p  0.05 were
onsidered significant.
The protocol was approved by the regional ethics committee.
ll patients gave written informed consent.
There were no differences in patient characteristics between
roups (1). Mean age was 57  9 years, 16% were women, and
eak creatine kinase-MB fraction mass was 369 g/l (interquartile
ange 220 to 444 g/l). All patients were treated with aspirin,
lopidogrel, a beta-blocker, an angiotensin-converting enzyme
nhibitor or angiotensin-receptor blocker, and a statin during
ollow-up. All had sinus rhythm during echocardiography, except
patient in the mBMC group with atrial fibrillation at baseline.
There were no differences between groups for variables of LV
unction during 12 months’ follow-up (Fig. 1). Also, when the total
atient population was dichotomized according to the median value
or left ventricular ejection fraction (LVEF) at baseline (45%), we did
ot find any significant treatment effect for LVEF, LV end-diastolic
olume, or wall motion score index, either for the baseline low or the
aseline high group. For the total population, LVEF increased by
.8  8.4% (p  0.01), and the wall motion score index decreased
y 0.23  0.24 (p  0.001) at 3 months, and both remained
ignificantly different from baseline. Left ventricular end-diastolic
olume increased by 9.8 28.7 ml (p 0.01) at 6 months but was
ot different at 3 and 12 months compared with baseline.
Moderate or severe mitral regurgitation was found in 2 patients
n each group at baseline (p  1.00) and in 5 patients in the
BMC group and 2 patients in the control group at 12 months
p  0.44). Moderate or severe aortic regurgitation was not
bserved in any patient at baseline or 12 months.
Holter monitoring revealed nonsustained ventricular tachycar-
ia in 7 mBMC group patients and in 9 control patients at baseline
p 0.62) and in 2 patients in each group at 6 months (p  1.00).
he number of premature ventricular contractions and variables
btained by signal-averaged ECG (filtered QRS width, high
requency low amplitude duration, and root mean square voltage)
as similar in both groups.
Quantitative coronary angiography of the LAD culprit lesion
evealed a mean decrease in the minimal luminal diameter of 0.4
.9 mm in the mBMC group and 0.5  0.6 mm in controls (p 
.18). Significant culprit lesion restenosis was found in 7 (14%)
atients in the mBMC group and 8 (16%) in the control group
p  0.88). Thirteen were treated with new PCI and 2 with
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February 12, 2008:674–7oronary artery bypass grafting. One patient in the mBMC group
nd 2 in the control group had PCI for nonculprit lesion LAD
tenosis at 6-month follow-up (p  1.00). There were no differ-
nces between groups in the number of adverse events (Table 1).
The main finding in this study is that injections of mBMC in
he LAD 4 to 8 days after anterior wall AMI did not improve
V function during 12-month follow-up. No data indicated
ncreased restenosis or arrhythmias. In the BOOST study,
agnetic resonance imaging results indicated that BMC ther-
py accelerates LV recovery, since LVEF only increased in the
reatment group at 6 months, whereas at 18 months, the
ncrease in LVEF was similar in both groups (4). In the present
tudy, we used echocardiography and found a similar improve-
ent in LV function in both groups after 3 months followed by
stable state over the next 9 months. Magnetic resonance
maging is regarded more sensitive than echocardiography to
etect changes in LV function. However, neither magnetic
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Figure 1 Changes in Left Ventricular Global
and Regional Function and Volumes
Data are mean  SD. Blue circles  mBMC group; red circles  control
group. LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular
ejection fraction; WMSI  wall motion score index. P  change between
groups over time (deviation from parallel time course).esonance imaging, single-photon emission computed tomog-
aphy, nor echocardiography showed any difference between
roups for changes in LVEF or left ventricular end-diastolic
olume at 6 months in the ASTAMI study (1).
Results of the REPAIR-AMI study suggest that mBMC treat-
ent improves the clinical outcome after AMI compared with
lacebo (5). In contrast, we found an excellent clinical outcome in
oth the treatment and the control group, concordant with other
tudies (6).
There are several possible explanations for why we did not find
n effect of cell therapy. The number of regenerative cells used may
ave been too small (7). It has also been suggested (8) that
lthough mBMC in ASTAMI were viable, cells may have been
unctionally impaired. However, bone marrow cells prepared accord-
ng to the ASTAMI protocol are functional in bone marrow trans-
lantation for patients with hematologic diseases (9), where homing
f cells, such as along the SDF-1/CXCR4-axis, is important for
herapeutic success (10). Furthermore, because the ASTAMI study
as powered to detect a difference of 5% of the change in LVEF (1),
ur results do not exclude a less pronounced effect of mBMC therapy.
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linical Events During 12-Month Follow-Up
Table 1 Clinical Events During 12-Month Follow-Up
mBMC
(n  50)
Control
(n  50) p Value
Mortality 0 0 1.00
Recurrent myocardial infarction 1 (2%) 0 1.00
Hospitalization for heart failure 2 (4%) 1 (2%) 1.00
All revascularization 13 (26%) 11 (22%) 0.64
Target-vessel PCI 11 (11%) 9 (18%) 0.62
Nontarget-vessel PCI 2 (4%) 0 0.50
CABG 3 (6%) 3 (6%) 1.00
Sustained ventricular arrhythmia 2 (4%) 1 (2%) 1.00
Syncope 3 (6%) 0 0.24
Other rehospitalization 9 (18%) 8 (16%) 0.79
alues are number of patients (proportion) who experienced clinical events during follow-up. Some
atients were revascularized with both PCI and CABG.
CABG  coronary artery bypass grafting; mBMC  mononuclear bone marrow cells; PCI 
ercutaneous coronary intervention.doi:10.1016/j.jacc.2007.10.032
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Blood 2005;106:1901–10.Letters to the Editorardiac Resynchronization
herapy and Atrial
achyarrhythmias: A Question
till Searching for an Answer
t is with great interest that we read the article in the September
5, 2007, issue of the Journal by Yannopoulos et al. (1). The
nding of reduced atrial tachyarrhythmia (AT) burden after
ardiac resynchronization therapy (CRT) implantation is indeed
n intriguing finding that is pleasing from a pathophysiological
nd clinical perspective. However, in reviewing the literature on
his topic, we feel that a contribution from our laboratory has been
eglected. We performed a retrospective analysis of 27 patients
ho failed CRT implantation at our institution and did not go on
o have an epicardial left ventricular (LV) lead surgically implanted
2). These patients were then matched, by gender, age, heart
ailure etiology, and history of atrial fibrillation (AF) with 2 CRT
atients, 1 responder, and 1 nonresponder. We found no difference
n AF burden between the CRT and non-CRT cohorts, using
evice-based diagnostics as the means of detecting ATs, although
RT patients with no history of AF did have a longer time to their
rst AF event. Our findings contradict those of the present study
nd are in agreement with those of Fung et al. (3).
The present study, while well performed, has certain flaws
orth mention. First, the exact method of determining the number
f AT episodes was not described. For example, would 2 4-s
ode-switch episodes occurring within 1 min be classified as
eparate events? It is more likely that this reflects a single AT event
hat is undersensed by the device, which then records separate
vents. For this reason, quantification of AT burden by mode-
witching episodes may be inaccurate. A second weakness is theates, and the longest and shortest AT episodes are less clinically
elevant than the total AT duration burden, especially given the
ropensity for devices to undersense AT. Thromboembolic risk
nd hemodynamic stress would seem to depend more upon
uration and total burden of AT, not the number of episodes. The
ercentage of AT episodes with saved electrograms is also an
mportant piece of omitted data. The atrial rates during AT
pisodes, in particular, are largely irrelevant. Whereas AF should
egister as a faster rate than an atrial tachycardia or flutter,
ndersensing of fibrillatory waves by the device (as graphically
llustrated in the printed electrograms) may paradoxically create
he opposite effect. Furthermore, ventricular response during atrial
achycardia and flutter is oftentimes more difficult to control than
F, making AT episodes with slower atrial rates potentially more
linically symptomatic. Finally, it would appear that AT episodes
efore CRT were quantified strictly from device counters without
eview, whereas episodes after CRT, when electrograms were
vailable, were reviewed. This may have led to overreporting of
vents before CRT, again, because of the propensity of devices to
ndersense ATs.
We do agree with the authors that studies examining AT
urden without implanted devices present in both groups (e.g., the
ARE-HF [Cardiac Resynchronization Heart Failure Study]
nalysis in patients with and without CRT [4]) are of little benefit.
etermining AF burden by random electrocardiograms has been
emonstrated to be of little clinical import, and Yannopoulos et al.
1) rightly emphasize that the presence of a device in only 1 group
ill invariably lead to inequities in detection.
Currently, the role of CRT in reducing atrial arrhythmias
emains speculative, as the only data come from retrospective or
ncontrolled studies. Unfortunately, in the present clinical climate,
he prospect of a prospective study examining this question is grim,
s are any studies with a true control group examining the effects
f CRT in selected populations. This is unfortunate, in that AT
urden may provide important objective evidence for a direct effect
